In 2012, Decressac and co‐workers demonstrated that the administration of NPY increased the survival of dopaminergic (DA) neurons in both in vitro and in vivo models of PD through direct interaction with the NPY's GPCR receptor Y2 (Decressac et al. 2012). This evidence concerns the gene PSMB8 and Parkinson disease.